Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

Presentation TCT 2023

Four-Year Outcomes From the EVOLUT Low Risk Trial

Presenter: Michael Reardon

October 24, 2023

Presentation ACC 2023

Transcatheter vs Surgical Aortic Valve Replacement in Low RiskPatients: 3-Year Outcomes from the EvolutLow Risk Trial

Presenter: John K. Forrest

March 05, 2023

Presentation TVT 2021

Complete 2-year Follow-Up from Evolut Low Risk Trial

Presenter: John Forrest

July 20, 2021

Presentation Cardiovascular Interventions 2019

Show me the Data: Key Clinical Trials of 2019

Presenter: Ehtisham Mahmud

November 01, 2019

Presentation TCT 2019

Deep-Dive: NEW Insights From the Evolut Low-Risk Trial

Presenter: Michael Reardon

September 26, 2019

Presentation TCT 2019

COAPT, Partner 2, and Evolut Low-Risk Trial Synopsis and What They Mean Moving Forward

Presenter: Elizabeth Perpetua

September 25, 2019

Presentation TVT 2019

Hemodynamic Outcomes and Predictors of Prosthesis-Patient Mismatch After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients: Results from the Evolut Low-Risk Trial

Presenter: Mubashir Mumtaz

June 14, 2019

Presentation TVT 2019

The Evolut Low-Risk Randomized Trial

Presenter: Steven Yakubov

June 13, 2019

Presentation ACC 2019

Primary Results From the Evolut Low Risk Trial

Presenter: Michael J. Reardon

March 17, 2019

Presentation The Structural Heart Disease Summit 2018

Evolut R Low-Risk

Presenter: Jeffrey J. Popma

June 21, 2018

Presentation TCT 2017

The Evolut R Low-risk Trial

Presenter: Jeffrey J. Popma

October 30, 2017

Presentation TCT 2016

Rationale for and Design of SAPIEN LOW RISK and EVOLUTE LOW RISK

Presenter: Michael Argenziano, Alec S. Vahanian, Patrick T. O'Gara

October 31, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Jeffrey J. Popma

October 30, 2016

Presentation TVT 2016

Study Design for the EVOLUT R Low-Risk Trial

Presenter: Jeffrey J. Popma

June 16, 2016

Advertisement

Four-Year Outcomes From the EVOLUT Low Risk Trial

Transcatheter vs Surgical Aortic Valve Replacement in Low RiskPatients: 3-Year Outcomes from the EvolutLow Risk Trial

Complete 2-year Follow-Up from Evolut Low Risk Trial

Show me the Data: Key Clinical Trials of 2019

Deep-Dive: NEW Insights From the Evolut Low-Risk Trial

COAPT, Partner 2, and Evolut Low-Risk Trial Synopsis and What They Mean Moving Forward

Hemodynamic Outcomes and Predictors of Prosthesis-Patient Mismatch After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients: Results from the Evolut Low-Risk Trial

The Evolut Low-Risk Randomized Trial

Primary Results From the Evolut Low Risk Trial

Evolut R Low-Risk

The Evolut R Low-risk Trial

Rationale for and Design of SAPIEN LOW RISK and EVOLUTE LOW RISK

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

Study Design for the EVOLUT R Low-Risk Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content